Mortality Among LVAD Recipients Ineligible for Clinical Trials

Mortality Among LVAD Recipients Ineligible for Clinical Trials

These findings suggest that while treatment for patients who are ineligible for left ventricular assist device (LVAD) trial inclusion should be weighed against medical management, more consideration could be given to designing... read more

Cost-effectiveness of Adrenaline for Out-of-Hospital Cardiac Arrest

Cost-effectiveness of Adrenaline for Out-of-Hospital Cardiac Arrest

Adrenaline was not cost-effective when only directly related costs and consequences are considered. However, incorporating the indirect economic effects associated with transplanted organs substantially alters cost-effectiveness,... read more

Allergic Reactions to COVID-19 Vaccine

Allergic Reactions to COVID-19 Vaccine

To date, the development of mRNA vaccines for the prevention of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a success story, with no serious concerns identified in the ongoing... read more

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

The mRNA-1273 vaccine showed 94.1% efficacy at preventing COVID-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. The trial enrolled 30,420 volunteers... read more

The Evolving Armamentarium of COVID-19 Therapeutics

The Evolving Armamentarium of COVID-19 Therapeutics

Multiple repositories have been created for the vast scientific outpouring of COVID-19 research. The NIH regularly updates its treatment guidelines, which will be the primary reference for this review. To cut to the... read more

Pfizer and BioNTech Speed Up Timeline for COVID-19 Vaccine

Pfizer and BioNTech Speed Up Timeline for COVID-19 Vaccine

Pfizer and its partner BioNTech plan to offer their Covid-19 vaccine to any clinical trial volunteer who received placebo by March 1, several months earlier than initially planned. The decision represents the conclusion... read more

Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19

Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19

Primary outcome in the RECOVERY trial and in the WHO REACT meta-analysis was 28-day mortality. Assessing 28-day mortality may not be the optimal outcome in a trial. Since patients with severe COVID-19 often require prolonged... read more

External Corroboration That Corticosteroids May Be Harmful to Septic Shock Endotype A Patients

External Corroboration That Corticosteroids May Be Harmful to Septic Shock Endotype A Patients

This exploratory analysis provides further evidence that corticosteroid exposure may be associated with increased mortality among septic shock endotype A patients. We previously reported gene expression-based endotypes... read more

The hospital of the future – building intelligent environments to facilitate safe and effective acute care delivery

The hospital of the future – building intelligent environments to facilitate safe and effective acute care delivery

Both the integrity of the healing professions and the safety of our patients hinge on our ability to identify and overcome barriers to effective, error-free care delivery. These barriers are not due to the lack of a sophisticated... read more

Harmonizing Heterogeneous Endpoints in COVID-19 Trials Without Loss of Information

Harmonizing Heterogeneous Endpoints in COVID-19 Trials Without Loss of Information

All ongoing clinical trials should include a stacked probability plot in their statistical analysis plan as descriptive analysis. While primary analysis should be on an early endpoint with appropriate capability to be... read more

NIH ACTIV trial of blood thinners pauses enrollment of critically ill COVID-19 patients

NIH ACTIV trial of blood thinners pauses enrollment of critically ill COVID-19 patients

Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients. Among critically ill COVID-19... read more

Weaning the patient: between protocols and physiology

Weaning the patient: between protocols and physiology

Ventilator weaning forms an integral part in critical care medicine and strategies to shorten duration are rapidly evolving alongside our knowledge of the relevant physiological processes. The purpose of the current review... read more

Oral Vitamin K Lowers the International Normalized Ratio More Rapidly

Oral Vitamin K Lowers the International Normalized Ratio More Rapidly

Oral vitamin K lowers INR more rapidly than subcutaneous vitamin K in asymptomatic patients who have supratherapeutic INR values while receiving warfarin. Warfarin therapy was withheld, and 1 mg of vitamin K was given... read more

Genetic Mechanisms of Critical Illness in COVID-19

Genetic Mechanisms of Critical Illness in COVID-19

Host-mediated lung inflammation is present, and drives mortality, in critical illness caused by COVID-19. Host genetic variants associated with critical illness may identify mechanistic targets for therapeutic development. Here... read more

Improved Oxygenation After Prone Positioning May Be a Predictor of Survival in Patients With ARDS

Improved Oxygenation After Prone Positioning May Be a Predictor of Survival in Patients With ARDS

We found a significant difference in the Pao2:Fio2 ratio after the first prone positioning between ICU survivors and nonsurvivors. The improvement in oxygenation after the first prone positioning was a significant predictor... read more

Myorelaxants in ARDS patients

Myorelaxants in ARDS patients

Neuromuscular blocking agents (NMBAs) inhibit patient-initiated active breath and the risk of high tidal volumes and consequent high transpulmonary pressure swings, and minimize patient/ ventilator asynchrony in acute respiratory... read more

Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion of People With HIV in Anti–PD1/PDL1 Trials

Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion of People With HIV in Anti–PD1/PDL1 Trials

This study identified encouraging trends in the inclusion of PLWH in anti–PD1/PDL1 cancer trials that occurred in the period following the initiation of CTEP advocacy. Work is needed to examine what impact this will have... read more